Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics has resumed patient dosing in its Phase 2 INVINCIBLE-4 study evaluating INT230-6 in presurgical triple-negative breast cancer in Switzerland. The trial restart follows a protocol amendment to address skin irritation issues, utilizing a lower drug-to-tumor volume ratio and a single injection of INT230-6.
Key figures
- Drug Name
- INT230-6
- Phase Of Trial
- Phase 2
- Patients treated prior
- 14
- Null hypothesis pcr rate
- 0.6
- Patients expected additional
- 47
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.